151556-31-9

Basic information

• Product Name: 1,1,1,2,2-pentafluoro-5-iodo-pentane
• Synonyms: 1,1,1,2,2-pentafluoro-5-iodo-pentane
• CAS NO: 151556-31-9
• Molecular Weight: 287.999
• Mol File: 151556-31-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1,1,1,2,2-pentafluoro-5-iodo-pentane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,1,2,2-pentafluoro-5-iodo-pentane(151556-31-9)
• EPA Substance Registry System: 1,1,1,2,2-pentafluoro-5-iodo-pentane(151556-31-9)

Safety Data

• Hazardous Substances Data: 151556-31-9(Hazardous Substances Data)

Usage

Type of compound

Perfluorinated alkyl iodide

Industrial applications

Building block in the synthesis of pharmaceuticals, agrochemicals, and functional materials

Properties

a. High thermal stability
b. Chemical resistance
c. Unique electronic properties
d. Low surface tension
e. High lipophobicity
f. Low dielectric constant

Reagent use

Valuable in organic synthesis

Specialized applications

Electronics industry

Presence of iodine atom

Potential candidate for various types of chemical transformations and derivatization reactions

Upstream product

• 148043-73-6 4,4,5,5,5-pentafluorpentan-1-ol 
• 209325-64-4 4,4,5,5,5-pentafluoropentyl-4-methylbenzene sulphonate 
• 252947-01-6 1-methanesulfonyloxy-4,4,5,5,5-pentafluoropentane 

Downstream Products

• 228569-81-1 1-benzyloxy-8,8,9,9,9-pentafluoro-nonane 

Relevant articles and documents

Agent for Preventing or Ameliorating Hearing Impairment

It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I0), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R3 is OH are used as an agent for preventing or improving hearing loss.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Metal salts of 3-methyl-chromane or thiochromane derivatives

The present invention relates to metal salts of 3-methyl-chromane or thiochromane derivatives, stereoisomers or hydrates thereof, and an anti-estrogenic pharmaceutical composition which comprises the above compound as an active component and exhibits a hi